BioCryst Pharmaceuticals
BCRX
BCRX
206 hedge funds and large institutions have $1.62B invested in BioCryst Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 74 increasing their positions, 55 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
10% more capital invested
Capital invested by funds: $1.48B → $1.62B (+$141M)
8.26% more ownership
Funds ownership: 57.74% → 66.01% (+8.3%)
5% more funds holding
Funds holding: 197 → 206 (+9)
Holders
206
Holding in Top 10
4
Calls
$77.9M
Puts
$38.7M
Top Buyers
| 1 | +$69.8M | |
| 2 | +$43M | |
| 3 | +$38.4M | |
| 4 |
BNP Paribas Asset Management
Paris,
France
|
+$26.2M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$20.9M |
Top Sellers
| 1 | -$20.4M | |
| 2 | -$14.5M | |
| 3 | -$11.4M | |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$7.99M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.72M |